<DOC>
	<DOCNO>NCT01114529</DOCNO>
	<brief_summary>The purpose study determine whether early Calcineurin Inhibitor ( CNI ) everolimus conversion 10-14 week post transplantation improve renal allograft function without compromise efficacy compare standard CNI treatment de novo renal allograft recipient . In addition , study design evaluate impact CNI-free regimen evolution cardiovascular parameter de novo renal allograft recipient</brief_summary>
	<brief_title>Efficacy , Safety Evolution Cardiovascular Parameters Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Baseline : Male female renal allograft recipient least 18 year old . Written informed consent . Patient receive primary secondary kidney transplant cadaveric living unrelated/related donor . Cold ischemia time ( CIT ) &lt; 24 hour . Negative pregnancy test female patient . Inclusion Criteria Randomization : Patients CNI ( TAC CsA ) + Myfortic + steroid . Serum creatinine &lt; 2.8 mg/dL ( 250 µmol/L ) actual eGFR ( MDRD4 ) ≥ 25 mL/min/1.73m exp2 ( without renal replacement therapy ) . Exclusion Criteria Baseline : Patients fulfil follow criterion eligible inclusion study : Recipient multiple organ transplant . Recipient ABO incompatible allograft positive crossmatch . Panel Reactive Antibodies ( PRA ) level ≥ 30 % . Positive test human immunodeficiency virus ( HIV ) . Patient receive allograft Hepatitis B surface Antigen ( HBsAg ) Hepatitis C Virus ( HCV ) positive donor . HBsAg and/or HCV positive patient evidence elevate LFTs ( ALT/AST level ≥ 2.5 time ULN ) . Severe restrictive obstructive pulmonary disorder . Patient severe allergy require acute chronic treatment hypersensitivity study drug similar drug . Severe hypercholesterolemia hypertriglyceridemia . Low platelet count . Low white blood cell count . History malignancy organ system Exclusion Criteria Randomization : Graft loss . Patient renal replacement therapy . Patient experience severe humoral and/or cellular rejection ( BANFF ≥ IIb ) . Patient ≥ 2 episode AR AR episode need antibody treatment . Patient ongoing currently treat AR ( 2 week prior randomization ) . Proteinuria &gt; 1 g/day . Patients recurrence Focal Segmental Glomerulosclerosis ( FSGS ) . Low platelet count ; Low white blood cell count ; Low absolute neutrophil count ; Low hemoglobin . Severe liver disease . Systemic infection require continue therapy would interfere objective study . Severe hypercholesterolemia hypertriglyceridemia . Patients ongoing wound heal problem , clinically significant infection require continue therapy . Presence intractable immunosuppressant complication side effect . Patients anticoagulants prevents renal allograft biopsy . Use prohibit medication . Use immunosuppressive agent utilized protocol . Pregnant nursing ( lactate ) woman . Women childbearing potential use highly effective method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>de novo renal allograft recipient</keyword>
	<keyword>renal allograft function</keyword>
	<keyword>CNI-free regimen</keyword>
</DOC>